Advertisement

Topics

Faraday Pharmaceuticals Announces First-In-Human Trial of FDY-5301

01:09 EDT 23 Sep 2016 | PR Newswire

SEATTLE, Sept. 23, 2016 /PRNewswire/ -- Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of elemental reducing agents for critical care medicine, today announced the start of a Phase 1 clinical trial evaluating its lead compound FDY-5301.

The randomized, double blind, placebo-controlled trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single, escalating, intravenous doses of FDY-5301 versus placebo in healthy volunteers. FDY-5301 contains elemental iodine in its reduced form – iodide – formulated for intravenous administration.

Preclinical data have demonstrated the ability of FDY-5301 to diminish reperfusion injury in both cardiac and skeletal muscle in a range of different animal models and in multiple species. The Phase 1 trial is being conducted in Australia and is targeted to enroll approximately 40 subjects.

"It's gratifying to begin this first-in-human study following the promising preclinical findings to date, and less than six months after our initial 'GLP' toxicity studies were initiated. Our elemental reducing agents have demonstrated compelling activity in a number of animal studies, including models of cardiac reperfusion, radiation injury and organ transplantation," said Stephen A. Hill, M.D., Chief Executive Officer of Faraday. "We are working hard on our Phase 2 preparations in hope of providing new options to patients as expeditiously as possible."

About Faraday

Faraday Pharmaceuticals is a biopharmaceutical company focused on the research and development of elemental reducing agents (ERAs). These therapeutic agents have potential applications for treatment of critical care illnesses. The company is headquartered in Seattle. For more information, visit www.faradaypharma.com.

Contact: 

Julie Rathbun 
Rathbun Communications
julie@rathbuncomm.com 
206.769.9219

Logo - http://photos.prnewswire.com/prnh/20150902/263316

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/faraday-pharmaceuticals-announces-first-in-human-trial-of-fdy-5301-300333152.html

SOURCE Faraday Pharmaceuticals

NEXT ARTICLE

More From BioPortfolio on "Faraday Pharmaceuticals Announces First-In-Human Trial of FDY-5301"

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Palliative Care
Palliative care is the active holistic care of patients with advanced progressive illness. Management of pain and other symptoms and provision of psychological, social and spiritual support is paramount. The goal of palliative care is achievement of the ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...